论文部分内容阅读
检测了４０例成人初治急性髓系白血病（ＡＭＬ）细胞ＣＤ＿（３４）抗原的表达，并分析了ＣＤ＿（３４）表达与一般临床特征、其它免疫标志、染色体异常及治疗效果的关系。结果显示，４０例ＡＭＬ中ＣＤ＿（３４）阳性表达１７例，占４２．５％，除Ｍ３无ＣＤ＿（３４）表达外，ＣＤ＿（３４）表达与ＦＡＢ亚型无关。组与组在年龄、性别、初诊时白细胞数、血红蛋白浓度、血小板计数、肝脾肿大及染色体异常均无显著差异。除淋系抗原在组表达明显增高外，其它髓系抗原表达在两组间无差异。组完全缓解率为４１．４８％，明显低于组的７３．９１％。研究提示，ＡＭＬ可能起源于较早期的造血于细胞恶性转化，检测ＣＤ＿（３４）表达对判断ＡＭＬ疗效有一定价值。
The expression of CD_(34) antigen in 40 patients with newly diagnosed acute myeloid leukemia (AML) cells was examined. The relationship between CD_(34) expression and general clinical characteristics, other immune markers, chromosomal abnormalities, and therapeutic effects was analyzed. The results showed that CD_ (34) was positive in 17 cases (42.5%) in 40 cases of AML. Except for M3 without CD_ (34), CD_ (34) expression was not related to FAB subtype. There was no significant difference in age, sex, white blood cell count, hemoglobin concentration, platelet count, hepatosplenomegaly, and chromosomal abnormalities at the initial diagnosis. With the exception of lymphoid antigen expression in the group, the expression of other myeloid antigens did not differ between the two groups. The complete remission rate was 41.48% in the group, which was significantly lower than the group’s 73.91%. Studies have shown that AML may originate from the early malignant transformation of hematopoietic cells, and detection of CD_(34) expression has a certain value in judging the efficacy of AML.